BIOGEN TECHNOLOGIES EUROPE SASU : revenue, balance sheet and financial ratios

BIOGEN TECHNOLOGIES EUROPE SASU is a French company founded 5 years ago, specialized in the sector Ingénierie, études techniques. Based in PARIS (75017), this company of category PME shows in 2024 a revenue of 23 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-18

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - BIOGEN TECHNOLOGIES EUROPE SASU (SIREN 898128525)
Indicator 2024 2023 2022
Revenue 22 835 € 4 050 € 17 040 €
Net income 5 536 € -4 965 € 1 680 €
EBITDA 5 762 € -5 065 € 1 953 €
Net margin 24.2% -122.6% 9.9%

Revenue and income statement

In 2024, BIOGEN TECHNOLOGIES EUROPE SASU achieves revenue of 23 k€. Over the period 2022-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +15.8%. Vs 2023, growth of +464% (4 k€ -> 23 k€). After deducting consumption (15 k€), gross margin stands at 8 k€, i.e. a rate of 36%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 6 k€, representing 25.2% of revenue. Positive scissor effect: EBITDA margin improves by +150.3 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 6 k€, i.e. 24.2% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

22 835 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

8 324 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

5 762 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

5 726 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

5 536 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

25.2%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 23%. The balance between equity and debt is satisfactory. Cash flow represents 24.2% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.0%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

23.275%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

24.243%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.0

Solvency indicators evolution
BIOGEN TECHNOLOGIES EUROPE SASU

Sector positioning

Debt ratio
0.0 2024
2022
2023
2024
Q1: 0.0
Med: 8.32
Q3: 42.94
Excellent -50 pts over 3 years

In 2024, the debt ratio of BIOGEN TECHNOLOGIES EUROP... (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
23.27% 2024
2022
2023
2024
Q1: 11.42%
Med: 37.88%
Q3: 61.37%
Average

In 2024, the financial autonomy of BIOGEN TECHNOLOGIES EUROP... (23.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
0.0 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.0 years
Q3: 0.9 years
Excellent -50 pts over 3 years

In 2024, the repayment capacity of BIOGEN TECHNOLOGIES EUROP... (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 130.34. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

130.335

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

0.0

Liquidity indicators evolution
BIOGEN TECHNOLOGIES EUROPE SASU

Sector positioning

Liquidity ratio
130.34 2024
2022
2023
2024
Q1: 149.17
Med: 230.27
Q3: 405.7
Watch

In 2024, the liquidity ratio of BIOGEN TECHNOLOGIES EUROP... (130.34) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Interest coverage
0.0x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.0x
Q3: 2.06x
Average

In 2024, the interest coverage of BIOGEN TECHNOLOGIES EUROP... (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 97 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 288 days. Excellent situation: suppliers finance 191 days of the operating cycle (retail model). Overall, WCR represents 236 days of revenue, i.e. 15 k€ to permanently finance. Over 2022-2024, WCR increased by +8767%, requiring additional financing.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

14 989 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

97 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

288 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

236 j

WCR and payment terms evolution
BIOGEN TECHNOLOGIES EUROPE SASU

Positioning of BIOGEN TECHNOLOGIES EUROPE SASU in its sector

Comparison with sector Ingénierie, études techniques

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (40 transactions). This range of 2 004€ to 16 334€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2024
Indicative
2k€ 5k€ 16k€
5 463 € Range: 2 004€ - 16 334€
NAF 5 année 2024

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 40 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Ingénierie, études techniques)

Compare BIOGEN TECHNOLOGIES EUROPE SASU with other companies in the same sector:

Voir toutes les statistiques du secteur Ingénierie, études techniques

Frequently asked questions about BIOGEN TECHNOLOGIES EUROPE SASU

What is the revenue of BIOGEN TECHNOLOGIES EUROPE SASU ?

The revenue of BIOGEN TECHNOLOGIES EUROPE SASU in 2024 is 23 k€.

Is BIOGEN TECHNOLOGIES EUROPE SASU profitable?

Yes, BIOGEN TECHNOLOGIES EUROPE SASU generated a net profit of 6 k€ in 2024.

Where is the headquarters of BIOGEN TECHNOLOGIES EUROPE SASU ?

The headquarters of BIOGEN TECHNOLOGIES EUROPE SASU is located in PARIS (75017), in the department Paris.

Where to find the tax return of BIOGEN TECHNOLOGIES EUROPE SASU ?

The tax return of BIOGEN TECHNOLOGIES EUROPE SASU is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does BIOGEN TECHNOLOGIES EUROPE SASU operate?

BIOGEN TECHNOLOGIES EUROPE SASU operates in the sector Ingénierie, études techniques (NAF code 71.12B). See the 'Sector positioning' section above to compare the company with its competitors.